CBMG
is a New York-based biopharmaceutical company that develops cell therapies for the treatment of cancer and degenerative diseases... Read moreCBMG
is a New York-based biopharmaceutical company that develops cell therapies for the treatment of cancer and degenerative diseases... Read more
News
Sep 27, 2023
Yahoo
CBMG: Nektar Therapeutics Announces New Clinical Study Collaboration with Cellular Biomedicine Group Inc. to Evaluate NKTR-255 in Combination with C-TIL051 in Advanced Non-Small Cell Lung Cancer
Jun 29, 2023
ChinaBio Today
CBMG: CBMG Out-Licenses Top Two CAR-T Candidates to Janssen for $245 Million Upfront
Jun 06, 2023
Medthority
CBMG: Janssen Biotech to collaborate with Cellular Biomedicine Group to develop and commercialise the next generation of CAR T-cell therapies
May 16, 2023
Medthority
CBMG: Janssen enters worldwide collaboration and license agreement with Cellular Biomedicine Group to develop next generation CAR-T therapies
May 04, 2023
PMLiVE
CBMG: Janssen signs $245m deal with Cellular Biomedicine for pair of CAR T-cell therapies
May 02, 2023
MedicalMarketing& Media
CBMG: Janssen strikes $245M licensing deal with Cellular Biomedicine Group for CAR-T cancer therapies
Apr 17, 2023
FinanzNachrichten
CBMG: Shanghai Cellular Biopharmaceutical Group Ltd.: Shanghai Cellular Biopharmaceutical Group presents first data from Phase I trial evaluating a novel CAR-T in advanced liver cancer at AACR Annual Meeting
Oct 31, 2022
Markets Insider
CBMG: Cellular Biomedicine Group Announces FDA Clearance of IND Application for Novel TIL Therapy C-TIL051
Jan 12, 2022
PR Newswire
Press Release: CBMG : CBMG Receives FDA Regenerative Medicine Advanced Therapy and Fast Track Designations for Bi-Specific Anti-CD19/CD20 CAR-T Cell Therapy for Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Dec 13, 2021
PR Newswire
Press Release: CBMG : CBMG Receives FDA Clearance of IND Application for Bi-Specific Anti-CD19/CD20 CAR-T Cell Therapy for Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
CBMG Competitors
1
2
3
4
5